Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

November 08, 2005 13:32 ET

Mistral Pharma Announces the Issuance of a US Patent for its Drug Delivery Technology

MONTREAL, QUEBEC--(CCNMatthews - Nov. 8, 2005) - Mistral Pharma Inc. (TSX VENTURE:MIP) announced today that the US Patent Office has granted a patent (US # 6,960,357) for its SAVIT drug delivery technology. Mistral's SAVIT technology is licensed from Savit Consulting Inc., a company held by Dr. Sham Chopra, inventor of the SAVIT technology and Mistral's Chief Scientific Officer.

"The issuance of this patent strengthens our intellectual property portfolio and increase the value of the SAVIT platform" said Mr. Bertrand F. Bolduc, Mistral's President & CEO. "Our SAVIT technology is a very interesting delivery platform which can be used for several drug profiles and at a very competitive cost of goods" he added.

This US Patent covers tablets made from a core partially covered with a coating controlling the release surface. Such tablets can release drug linearly with time, or at controlled-variable rate with time. The controlled-variability is obtained by using cores of different shapes. One additional advantage of SAVIT is that it can accommodate superior drug loads.

About Mistral Pharma Inc.

Mistral Pharma is an emerging oral drug delivery company which develops generic and branded controlled-delivery products using its PROCISE™, SAVIT™ and CHRONOP™ geometry surface area technologies. These technologies offer many competitive advantages including flexible and fast development, competitive cost of goods and the use of "generally recognized as safe" excipients. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    (514) 920-0909 ext.24
    bbolduc@mistralpharma.com
    or
    Mistral Pharma Inc.
    Alain Provencher, CA
    Vice-president, Finance & Chief Financial Officer
    (514) 920-0909 ext. 22
    aprovencher@mistralpharma.com